Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesUrologyDevoted Health HIFU Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentDevoted HealthPolicy MM.76

    High-intensity focused ultrasound for prostate cancer

    Customize your policy alerts

    Sign up for devoted_health Policy MM.76 alerts

    Get alerted when Policy MM.76 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of high-intensity focused ultrasound (HIFU) therapy for prostate cancer and applies to all Devoted Health plans. HIFU is considered medically necessary for recurrent, localized prostate cancer.

    Policy Summary
    PayerDevoted Health
    PolicyHigh-intensity focused ultrasound for prostate cancer
    Policy CodePolicy MM.76
    Change TypeAnnual update
    Effective DateSeptember 9, 2024
    Next Review DateSeptember 1, 2026
    Key ActionConfirm that HIFU is being used to treat recurrent, localized prostate cancer.
    SourceLink
    POLICY UPDATE CHANGES

    The policy underwent an annual update on September 8, 2025.

    All plansPlan applicability
    Recurrent, localizedMedically necessary setting
    55880Applicable HIFU code
    15Active or recruiting HIFU trials
    2BNCCN category

    Medical Necessity Criteria

    Medically Necessary Indication

    HIFU is considered medically necessary when used for treatment of recurrent, localized prostate cancer.

    Medical necessity: The patient has recurrent, localized prostate cancer and HIFU is being used to treat that condition.

    The policy states this condition is medically necessary; no additional clinical criteria are specified.

    Applicable Codes

    Applicable codesCPTCovered
    55880Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance

    Coverage Considerations

    Denial Risk
    Policy Summary
    PayerDevoted Health
    PolicyHigh-intensity focused ultrasound for prostate cancer
    Policy CodePolicy MM.76
    Change TypeAnnual update
    Effective DateSeptember 9, 2024
    Next Review DateSeptember 1, 2026
    Key ActionConfirm that HIFU is being used to treat recurrent, localized prostate cancer.
    SourceLink
    On This Page
    Medical Necessity CriteriaApplicable CodesCoverage ConsiderationsClinical BackgroundKey Terms

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Disease Setting Does Not Meet Coverage Criterion

    HIFU is considered medically necessary only for treatment of recurrent, localized prostate cancer. Flag cases in which HIFU is used for primary localized prostate cancer or another disease setting because the coverage criterion is not met.

    Clinical Background

    High-intensity focused ultrasound (HIFU) is a noninvasive treatment that uses concentrated ultrasound waves to thermally ablate part or all of the cancerous prostate gland. By targeting prostate tissue with heat, HIFU may avoid some morbidity associated with more invasive treatments such as prostatectomy, including adverse effects on urinary and sexual function. This policy addresses HIFU for the treatment of recurrent, localized prostate cancer.

    Key Terms

    Definition
    HIFUHigh-intensity focused ultrasound
    Definition
    PCaProstate cancer
    Definition
    CMSCenters for Medicare and Medicaid Services
    Definition
    LCDLocal Coverage Determinations
    Definition
    MCDCMS Medicare Coverage Database
    Definition
    NCDNational Coverage Determination
    Definition
    UMUtilization Management